Recombinant Human ALK protein (rFc Tag)

种属

Human

纯度

>90 %, SDS-PAGE

标签

rFc Tag

生物活性

未测试

Cat no : Eg3796

Print datasheet

Synonyms

ALK tyrosine kinase receptor, Anaplastic lymphoma kinase, CD246, EC:2.7.10.1



产品信息

纯度 >90 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性
Not tested
来源 HEK293-derived Human ALK protein Val19-Ser1038 (Accession# Q9UM73) with a rabbit IgG Fc tag at the C-terminus.
基因ID 238
蛋白编号 Q9UM73
预测分子量 136.6 kDa
SDS-PAGE 125-135 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

ALK, also named as CD246, is a receptor tyrosine kinase (RTK) that belongs to the protein kinase superfamily. ALK is usually found in the nervous system and appears to play an important role in the normal development and function of the nervous system. ALK was originally identified as part of the NPM (Nucleophosmin)-ALK oncogenic fusion protein, resulting from the (2;5)(p23;q35) translocation that is frequently associated with anaplastic large-cell lymphoma (ALCL). The EML4 (echinoderm microtubule-associated protein-like 4)-ALK fusion protein have been described in non-small-cell lung cancer (NSCLC), this transforming fusion kinase is a promising candidate for a therapeutic target as well as for a diagnostic molecular marker in NSCLC. The expression of anaplastic lymphoma kinase (ALK, CD246) has been documented in most uIMTs.

参考文献:

1. Soda M.et al. (2007). Nature. 448(7153):561-6. 2. Parra-Herran C. (2021). Int J Gynecol Pathol. 40(1):28-31.